BR112022005420A2 - Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina - Google Patents
Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-aminaInfo
- Publication number
- BR112022005420A2 BR112022005420A2 BR112022005420A BR112022005420A BR112022005420A2 BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2 BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2
- Authority
- BR
- Brazil
- Prior art keywords
- chlorobenzyl
- triazol
- piperidin
- methyl
- morpholino
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- STWVLEKJQQRGMO-GUYCJALGSA-N 3-[4-[(2S,5S)-5-[(4-chlorophenyl)methyl]-2-methylmorpholin-4-yl]piperidin-1-yl]-1H-1,2,4-triazol-5-amine Chemical compound ClC1=CC=C(C[C@@H]2N(C[C@@H](OC2)C)C2CCN(CC2)C=2NC(=NN=2)N)C=C1 STWVLEKJQQRGMO-GUYCJALGSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905494P | 2019-09-25 | 2019-09-25 | |
| PL43126919 | 2019-09-25 | ||
| PCT/IB2020/058984 WO2021059220A1 (en) | 2019-09-25 | 2020-09-25 | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022005420A2 true BR112022005420A2 (pt) | 2022-06-21 |
Family
ID=73139065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022005420A BR112022005420A2 (pt) | 2019-09-25 | 2020-09-25 | Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11746107B2 (https=) |
| EP (1) | EP4041726B8 (https=) |
| JP (1) | JP7697933B2 (https=) |
| KR (1) | KR20220069008A (https=) |
| CN (1) | CN114466845B (https=) |
| AU (1) | AU2020356534B2 (https=) |
| BR (1) | BR112022005420A2 (https=) |
| CA (1) | CA3155177A1 (https=) |
| ES (1) | ES3056105T3 (https=) |
| IL (1) | IL291569B2 (https=) |
| MX (1) | MX2022002881A (https=) |
| PH (1) | PH12022550713A1 (https=) |
| PL (1) | PL4041726T3 (https=) |
| TW (3) | TWI769532B (https=) |
| WO (1) | WO2021059220A1 (https=) |
| ZA (1) | ZA202204542B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022002881A (es) | 2019-09-25 | 2022-06-08 | Oncoarendi Therapeutics Sa | Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2802530B1 (fr) * | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| ATE354568T1 (de) * | 2000-08-08 | 2007-03-15 | Ortho Mcneil Pharm Inc | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
| PE20142366A1 (es) * | 2012-05-30 | 2015-01-10 | Hoffmann La Roche | Compuestos triazolo como inhibidores de pde 10 |
| EP3082805B1 (en) * | 2013-12-20 | 2020-02-05 | Institute for Drug Discovery, LLC | Substituted amino triazoles, and methods using same |
| US9440953B2 (en) | 2014-12-19 | 2016-09-13 | OncoArendi Therapeutics Sp. z o.o. | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| PL415078A1 (pl) * | 2015-09-04 | 2017-03-13 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
| MX2022000306A (es) | 2019-07-15 | 2022-03-11 | Oncoarendi Therapeutics Sa | Amino triazoles sustituidos utiles como inhibidores de quitinasa. |
| MX2022002881A (es) | 2019-09-25 | 2022-06-08 | Oncoarendi Therapeutics Sa | Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. |
-
2020
- 2020-09-25 MX MX2022002881A patent/MX2022002881A/es unknown
- 2020-09-25 TW TW109133211A patent/TWI769532B/zh active
- 2020-09-25 KR KR1020227009777A patent/KR20220069008A/ko active Pending
- 2020-09-25 JP JP2022519042A patent/JP7697933B2/ja active Active
- 2020-09-25 PL PL20803247.4T patent/PL4041726T3/pl unknown
- 2020-09-25 TW TW111121583A patent/TWI849432B/zh active
- 2020-09-25 BR BR112022005420A patent/BR112022005420A2/pt unknown
- 2020-09-25 CA CA3155177A patent/CA3155177A1/en active Pending
- 2020-09-25 TW TW113127475A patent/TWI892762B/zh active
- 2020-09-25 CN CN202080067709.7A patent/CN114466845B/zh active Active
- 2020-09-25 ES ES20803247T patent/ES3056105T3/es active Active
- 2020-09-25 US US17/032,232 patent/US11746107B2/en active Active
- 2020-09-25 PH PH1/2022/550713A patent/PH12022550713A1/en unknown
- 2020-09-25 AU AU2020356534A patent/AU2020356534B2/en active Active
- 2020-09-25 IL IL291569A patent/IL291569B2/en unknown
- 2020-09-25 EP EP20803247.4A patent/EP4041726B8/en active Active
- 2020-09-25 WO PCT/IB2020/058984 patent/WO2021059220A1/en not_active Ceased
-
2022
- 2022-04-22 ZA ZA2022/04542A patent/ZA202204542B/en unknown
-
2023
- 2023-07-17 US US18/222,679 patent/US12319677B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022549863A (ja) | 2022-11-29 |
| PL4041726T3 (pl) | 2026-02-23 |
| ZA202204542B (en) | 2023-01-25 |
| EP4041726B1 (en) | 2025-09-17 |
| EP4041726A1 (en) | 2022-08-17 |
| CN114466845B (zh) | 2024-12-17 |
| IL291569B1 (en) | 2024-12-01 |
| EP4041726C0 (en) | 2025-09-17 |
| TW202448877A (zh) | 2024-12-16 |
| IL291569A (en) | 2022-05-01 |
| PH12022550713A1 (en) | 2024-02-12 |
| IL291569B2 (en) | 2025-04-01 |
| JP7697933B2 (ja) | 2025-06-24 |
| WO2021059220A1 (en) | 2021-04-01 |
| CA3155177A1 (en) | 2021-04-01 |
| EP4041726B8 (en) | 2025-11-26 |
| US20210147401A1 (en) | 2021-05-20 |
| CN114466845A (zh) | 2022-05-10 |
| TW202126644A (zh) | 2021-07-16 |
| TWI769532B (zh) | 2022-07-01 |
| US20240025889A1 (en) | 2024-01-25 |
| AU2020356534A1 (en) | 2022-05-19 |
| TWI849432B (zh) | 2024-07-21 |
| ES3056105T3 (en) | 2026-02-18 |
| US11746107B2 (en) | 2023-09-05 |
| US12319677B2 (en) | 2025-06-03 |
| MX2022002881A (es) | 2022-06-08 |
| AU2020356534B2 (en) | 2026-04-09 |
| KR20220069008A (ko) | 2022-05-26 |
| TWI892762B (zh) | 2025-08-01 |
| TW202237594A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
| EP4279488A4 (en) | PROCESS FOR THE SYNTHESIS OF AN AMINOPYRIMIDINE FAK INHIBITOR COMPOUND | |
| CY1118475T1 (el) | Αντιοξειδωτικοι ρυθμιστες φλεγμονης: c-17 ομολογοποιημενα παραγωγα ολεανολικου οξεος | |
| CY1116333T1 (el) | Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr | |
| MA49879A (fr) | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca | |
| PE20171738A1 (es) | Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos | |
| CO7170165A2 (es) | Fabricación de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acético | |
| DOP2013000072A (es) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino. | |
| BR112015019627A2 (pt) | amidas heterocíclicas como inibidores de quinases | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| CO2018005941A2 (es) | Formas sólidas de éster etílico del ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un método de preparación | |
| CY1124381T1 (el) | Παραγωγα οξαδιαζολοπυριδινης για χρηση ως αναστολεις της ο-ακυλο τρανσφερασης της γκρελινης | |
| BR112013004624A2 (pt) | "derivados de furopiridina" | |
| UY31004A1 (es) | Formas cristalinas de la [3-(4-{ 2-butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenixi)-propil]-dietil-amina | |
| BR112014032229A2 (pt) | método para produção de 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il) piridina-2-carbonitrila, e intermediários da mesma | |
| PH12020551169A1 (en) | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| BR112022005420A2 (pt) | Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina | |
| NZ595823A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| EA201792543A1 (ru) | Кристаллическая форма соединения (s)-3-{4-[5-(2-циклопентил-6-метоксипиридин-4-ил)-[1, 2,4]оксадиазол-3-ил]-2-этил-6-метилфенокси}пропан-1,2-диола | |
| MY208965A (en) | Use of n-functionalized alkoxy pyrazole compounds as nitrification inhibitors | |
| BR112022003171A2 (pt) | Processo para a síntese de compostos de pirazolidinona | |
| MX382683B (es) | Composiciones azeotrópicas de 1,3,3-tricloro-1,1-difluoropropano y fluoruro de hidrógeno. | |
| AR110998A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
| CR20160165A (es) | Acetato de 4-{4-[(1 e)-4-(2,9- diazaespiro [5.5] undec-2-il) but-1 -en-i -il]-2- metilbencil}-5-(propan-2-il) -1h-pirazol-3-ilo beta-d- glucopiranósido | |
| BR112017026286A2 (pt) | forma cristalina de n-(4-cloro-3-(5-oxo-1-(4-(trifluorometil)fenil)-4,5-di-hidro-1h-1,2,4-triazol-3-il)benzil)pivalamida, forma amorfa, composto cristalino e processo para a preparação da forma cristalina de n-(4-cloro-3-(5-oxo-1-(4-(trifluorometil)fenil)-4,5-dihidro-1h-1,2,4-triazol-3-il)benzil)pivalamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MOLECURE SPOLKA AKCYJNA (PL) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |